Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 2/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | MAP2 | P11137 | 1/20 | 0.32 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4002866 | 0.74 | MAP2K1 (0.35) | CCNCCDK8MAP2K1PARP1KDM4E | |
| SCHEMBL4007974 | 0.73 | MAP2K1 (0.34) | RHEBCCNCCDK8NUDT1MAP2K1 | |
| SCHEMBL16008410 | 0.69 | KDM4E (0.47) | NUDT1PARP1MAP2HTTKMT2A | |
| SCHEMBL5091387 | 0.69 | MAP2K1 (0.33) | RHEBCCNCCDK8NUDT1MAP2K1 | |
| SCHEMBL29063457 | 0.67 | CCNC (0.45) | RHEBCCNCCDK8NUDT1MAP2K1 | |
| SCHEMBL4000960 | 0.67 | MAP2K1 (0.34) | MAP2K1 | |
| SCHEMBL4002300 | 0.67 | MAP2K1 (0.41) | MAP2K1 | |
| SCHEMBL175459 | 0.66 | LOXL2 (0.54) | PARP1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL29751000 | 0.66 | LOXL2 (0.54) | PARP1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL17362824 | 0.64 | MKNK1 (0.42) | RHEBCCNCCDK8NUDT1MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ALCON INC. (CH) | 2008-07-03 | — | — | US | claimed |
| US-10624882-B2 | Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| EP-2068878-B1 | RHO KINASE INHIBITORS | AERIE PHARMACEUTICALS INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20180344723-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2018-12-06 | — | — | US | disclosed |
| US-20160243102-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2016-08-25 | — | — | US | disclosed |
| US-20150297581-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2015-10-22 | — | — | US | disclosed |
| US-20140357652-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2014-12-04 | — | — | US | disclosed |
| US-8809326-B2 | Isoquinolinone Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243102-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | RHEB 112/4885CCNC 1239/4885CDK8 515/4885 |
| US-20150297581-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | RHEB 112/4885CCNC 1239/4885CDK8 515/4885 |
| US-10624882-B2 | Rho kinase inhibitors | ROCK1, ROCK2, CIT | RHEB 112/4885CCNC 1239/4885CDK8 515/4885 |
| US-20140357652-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | RHEB 112/4885CCNC 1239/4885CDK8 515/4885 |
| US-20180344723-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | RHEB 112/4885CCNC 1239/4885CDK8 515/4885 |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ROCK1, ROCK2, ARHGDIA | RHEB 103/4885CCNC 1975/4885CDK8 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.